A B S T R A C T Background
Interplays between Mycobacterium tuberculosis, the etiological agent of tuberculosis (TB) in human and host professional phagocytes, namely macrophages (M/s) and dendritic cells (DCs), are central to immune protection against TB and to TB pathogenesis. We and others have recently shown that the C-type lectin dendritic cell-specific intercellular adhesion molecule-3 grabbing nonintegrin (DC-SIGN; CD209) mediates important interactions between mycobacteria and human monocyte-derived DCs (MoDCs) in vitro.
Methods and Findings
In order to explore the possible role of DC-SIGN in M. tuberculosis infection in vivo, we have analysed DC-SIGN expression in broncho-alveolar lavage (BAL) cells from patients with TB (n ¼ 40) or with other non-mycobacterial lung pathologies, namely asthma (n ¼ 14) and sarcoidosis (n ¼ 11), as well as from control individuals (n ¼ 9). We show that in patients with TB, up to 70% of alveolar M/s express DC-SIGN. By contrast, the lectin is barely detected in alveolar M/s from all other individuals. Flow cytometry, RT-PCR, and enzyme-linked immunosorbent assay analyses of BAL-derived fluids and cells indicated that M. tuberculosis infection induces DC-SIGN expression in alveolar M/s by a mechanism that is independent of Toll-like receptor-4, interleukin (IL)-4, and IL-13. This mechanism most likely relies on the secretion of soluble host and/or mycobacterial factors that have yet to be identified, as both infected and uninfected bystander M/s were found to express DC-SIGN in the presence of M. tuberculosis. Immunohistochemical examination of lung biopsy samples from patients with TB showed that the bacilli concentrate in pulmonary regions enriched in DC-SIGN-expressing alveolar M/s in vivo. Ex vivo binding and inhibition of binding experiments further revealed that DC-SIGNexpressing alveolar M/s constitute preferential target cells for M. tuberculosis, as compared to their DC-SIGN À counterparts. In contrast with what has been reported previously in MoDCs in vitro, ex vivo DC-SIGN ligation by mycobacterial products failed to induce IL-10 secretion by alveolar M/s, and IL-10 was not detected in BALs from patients with TB.
Conclusion
Altogether, our results provide further evidence for an important role of DC-SIGN during TB in humans. DC-SIGN induction in alveolar M/s may have important consequences on lung colonization by the tubercle bacillus, and on pulmonary inflammatory and immune responses in the infected host.
Introduction
Interactions between Mycobacterium tuberculosis, the airborne agent of tuberculosis (TB) in human and host phagocytes, namely macrophages (M/s) and dendritic cells (DCs), are central to anti-mycobacterial immunity and to TB pathogenesis [1, 2] . In particular alveolar M/s constitute a primary niche for the tubercle bacillus [3] . At the molecular level, interactions between the bacillus and host phagocytes rely on a variety of cellular receptors, among which the C-type lectin DC-specific intercellular adhesion molecule-3 grabbing nonintegrin (DC-SIGN; CD209) has recently received particular attention. Initially described as an HIV gp120 receptor [4, 5] , DC-SIGN has afterwards been shown to allow monocytederived DCs (MoDCs) to recognize a variety of microbes, including viruses, parasites, and bacteria [6] . A set of recent reports has established that DC-SIGN plays a key role in mycobacteria interactions with DCs, at least in vitro [7, 8] . Indeed, DC-SIGN allows human MoDCs to recognize members of the M. tuberculosis complex through lipoarabinomannan (LAM), an abundant lipoglycan of the mycobacterial envelope [7, 9] , and through other molecules, such lipomannan, arabinomannan, and the 19 kDa antigen [8] ; and DC-SIGN ligation by LAM partially inhibits the maturation of bacterial lipopolysaccharide (LPS)-stimulated MoDCs and potentiates the secretion of the anti-inflammatory cytokine interleukin (IL)-10 by these cells [8] . DC-SIGN interactions with mycobacteria or mycobacterial products may thus be of benefit for either the pathogen, by down-modulating DC functions, or for the host, by limiting tissue inflammation and immunopathology [11] [12] [13] . It is noteworthy that DC-SIGN is expressed by human pulmonary DCs [7, 14] , and mycobacteria-derived antigens have been detected in DC-SIGN þ DCs in lymph nodes from patients with TB, suggesting that interactions between the lectin and the bacillus may occur during the natural course of infection [7] . In order to further our understanding of the role of DC-SIGN in vivo, we have analysed the expression of the lectin in broncho-alveolar lavage (BAL) cells from patients with TB, as compared to cells from other patients.
Methods

Patients and Samples
Individuals studied (n ¼ 74; mean age 17.6 6 19.3 y; median age 10.5 y; 54% males) included patients with TB (n ¼ 40), sarcoidosis (n ¼ 11), or asthma (n ¼ 14). Other individuals had alveolar proteinosis (n ¼ 1), tracheal obstruction (n ¼ 1), tracheal surgery (n ¼ 1), inactive TB (n ¼ 5), and lymphoma (n ¼ 1). These individuals (n ¼ 9) are considered as controls in the rest of the study. All individuals were HIV negative and non-smokers. None were receiving anti-mycobacterial therapy and/or corticosteroids at the time of biopsy, except for the treatment of asthma. TB was diagnosed by smear observation and/or bacterial culture and/or clinical symptoms. Asthma was defined as a history of recurrent wheezing episodes and daily use of asthma medication. The diagnosis of sarcoidosis was based on previously described criteria [16] . Inactive TB refers to patients who had a previous history of TB (which was successfully treated) without reactivation. BAL fluids were performed as previously described [17] for diagnostic purpose. Blood mononuclear cells from healthy volunteers (Etablissement Franç ais du Sang, Paris, France) and from TB patients with smear observation were isolated by Ficoll-Paque (Pharmacia, Uppsala, Sweden) centrifugation. Only fluids in surplus were used in this study, according to institutional guidelines. Alveolar M/s Isolation, Treatment, and Infection BAL cells were washed and cultured in RPMI-1640 (Invitrogen, Carlsbad, California, United States) supplemented with 10% heat-inactivated foetal calf serum (FCS; Dutscher, Brumath, France) and 2 mM L-glutamine in Petri dishes for 1 h at 37 8C before removing nonadherent cells. When required, cells were treated with IL-4 (10 ng/ml, R&D Systems), tumor necrosis factor (TNF)-a (50 ng/ml; R&D Systems, Minneapolis, Minnesota, United States), Escherichia coli-derived LPS (100 ng/ml; Sigma, St. Louis, Missouri, United States), or a green fluorescent protein (GFP)-expressing strain of M. tuberculosis H37Rv (pEGFP plasmid was a kind gift from G. R. Stewart, University of Surrey, United Kingdom) at a multiplicity of infection (MOI) of one bacterium per cell.
THP1 Cell
THP1 (ATCC TIB-202) cells were transduced with a lentiviral DC-SIGN-encoding vector [18] . DC-SIGN-expressing cells were positively selected by flow cytometry-based cell sorting and cultivated, as THP1 cells, in RPMI-1640 supplemented with 10% heat-inactivated FCS and 2 mM Lglutamine.
Flow Cytometry
Cells were treated and analysed as previously described [19] . The following monoclonal antibodies (mAbs) were used: antiCD11b-PE, anti-CD11c-PE, anti-CD16-PE, anti-CD32-PE, anti-CD40-PE, anti-CD64-FITC, and anti-CD206-PE (all from Beckman Coulter, Allendale, New Jersey, United States); antiCD1a-PE, anti-CD11b-APC, anti-CD14-PE, anti-CD83-PE, anti-CD86-PE, anti-CD123-PE-Cy5, and anti-human leukocyte antigen (HLA)-DR-PE (all from BD Biosciences, San Diego, California, United States); anti-CD209 (DC-SIGN)-FITC and anti-PE (clone 120507; R&D Systems); anti-TLR2-PE, anti-TLR4-PE, and anti-TLR9-PE (all from eBioscience, San Diego, California, United States); and anti-BDCA-1-APC, anti BDCA-2-PE, and anti-BDCA-3-PE (all from Miltenyi Biotech, Bergisch Gladbach, Germany). Isotype controls were all purchased from BD Biosciences. Fluorescence was analyzed using FACScalibur and CellQuest Pro software (BD Biosciences).
Binding Experiments
Total BAL cells were pre-incubated for 30 min at 37 8C, according to a previously published procedure [20] , in RPMI-1640 containing 10% FCS and eventually containing isotype controls, either a mix of PE-conjugated and unconjugated anti-DC-SIGN antibodies (clones 120507 and 1B10, a kind gift from A. Amara, Institut Pasteur, Paris, France) or a mix of APCconjugated and unconjugated anti-CD11b antibodies (clones M1/70 [BD Biosciences] and 2LPM19c1 [Dako, Glostrup, Denmark]). All antibodies were used at 10 lg/ml. Preincubation at 37 8C in the presence of antibodies resulted in partial internalization of the corresponding receptors but did not decrease cell-associated fluorescence, because a mix of unlabelled and fluorescently labelled antibodies was used during this step (data not shown). Cells were then infected with GFP-expressing M. tuberculosis H37Rv, at a multiplicity of infection of five bacteria per cell, for 4 h at 4 8C to allow binding without phagocytosis. Cells were then washed in RPMI-1640 and further stained with PE-conjugated anti-DC-SIGN and APC-conjugated anti-CD11b antibodies for 30 min at 4 8C.
Cells were then analyzed by flow cytometry. Binding to THP1 and THP1::DC-SIGN cells was realized as previously described for DC-SIGN-expressing HeLa cells [7] . Inhibition of binding was realized using anti-DC-SIGN antibodies at 10 lg/ml. Enzyme-Linked Immunosorbent Assay BAL fluids were centrifuged for 15 min at 1000 3 g and supernatants were concentrated three to eight times using Ultra-15 and YM-5 concentrators (Amicon; Millipore, Billerica, Massachusetts, United States). Concentrated BAL fluids were analyzed for IL-4, IL-10, and IL-13 using high-sensitivity enzyme-linked immunosorbent assay (ELISA) kits from R&D Systems. The minimal detectable dose of IL-4, IL-10, and IL-13 was 0.11 pg/ml, ,0.5 pg/ml, and ,32 pg/ml, respectively. For analysis of alveolar M/ supernatants, M/s were cultured in Petri dishes for 1 h before removing non-adherent cells. Adherent cells were further incubated for 18 h in medium with or without E. coli LPS (10 ng/ml, Sigma), LAM (10 lg/ml; gift from G. Puzo, IPBS, Toulouse, France), anti-DC-SIGN antibodies (50 lg/ml, clones 1B10 and 120507), and isotype control (50 lg/ml). IL-10 in culture supernatant was then measured by ELISA (high-sensitivity kit, R&D Systems).
Immunohistochemistry
Lung biopsies were stained for DC-SIGN and M. tuberculosis using a DC-SIGN antibody (clone 1B10) and a homemade anti-M. bovis BCG polyclonal rabbit serum, respectively, as previously described [19] .
Confocal Microscopy
M/s were allowed to adhere for 15 min on polylysinecoated cover slips before fixation. Cells were then permeabilized with 0.05% saponin, immunostained, and analysed as described [19] . DC-SIGN was detected using clone 120507 mAb and a Cy3-conjugated secondary mAb (Amersham, Little Chalfont, United Kingdom). Examination was realized using a confocal microscope (Zeiss, Oberkochen, Germany) and the software LSM 510 v3.2 (Zeiss).
RT-PCR
Cells were recovered and homogeneized in Trizol (GIBCO BRL/Invitrogen, Carlsbad, California, United States). Total RNAs were extracted by classical chloroform procedure. Purified RNAs (100 ng) were used to amplify the DC-SIGN and GAPDH (glyceraldehyde-3-phosphate dehydrogenase) transcripts using the Onestep RT-PCR kit (Qiagen, Valencia, California, United States). Oligonucelotides hCD209F (59-ATTTTC CAACTCATTTTCAGCC-39) and hCD209R (59-TCTCACAGAAAGAGGAGGACAC-39) were used to amplify a 193-base pair product in the exon 7 of DC-SIGN.
O l i g o n u c e l o t i d e s G A P D H R T 1 ( 5 9-G A G T C A A C G G A T T T G G T C G T A T -3 9)
and GAPDHRT2 (59-AGTCTTCTGGGTGGCAGTGAT-39) were used to amplify a 542-base pair product from exons 2 to 8 of GAPDH. Reverse transcription was conducted for 30 min at 50 8C. PCR consisted of 15-min activation (95 8C), and 35 cycles of 1-min denaturation (94 8C), 1-min annealing (55 8C), and 1-min elongation (72 8C). RT-PCR products were analyzed on a 1% agarose gel.
Results
Alveolar CD11b-Expressing Cells Over-Express DC-SIGN in Patients with TB
Given the important role of DC-SIGN in mycobacterial interactions with human MoDCs in vitro [7] [8] [9] , we asked whether the lectin might interact with the tubercle bacillus during the natural course of TB in vivo in the lungs. Flow cytometry analysis of BAL cells from TB patients typically showed two major cell populations ( Figure 1A, upper Figure 1A , lower left and right panels). Results obtained for all individuals included in the study are shown in Figure 1B . infiltrates outside granulomas and were tightly associated with bacilli (representative result from one patient is shown in Figure 1C ). By contrast, and in accordance with results from flow cytometry, very few DC-SIGN-expressing cells were detected inside and outside granulomas in lung biopsy samples from patients with sarcoidosis (n ¼ 3; representative result from one patient is shown in Figure 1D ).
Alveolar DC-SIGN-Expressing Cells in Patients with TB Are M/s
The ability of CD11b þ DC-SIGN þ BAL cells to bind to the plastic (Figure 2A ), together with their morphology ( Figure  2B ), strongly suggested a M/ phenotype. In order to precisely define this phenotype, BAL cells from patients with TB were stained for DC-SIGN and for a number of markers specific to various DC subtypes, monocytes, and M/s, and were analyzed by flow cytometry (Figure 2C and 2D Figure 2C and 2D, DC-SIGN-expressing cells were clearly negative for BDCA-1 and BDCA-2. Cells were also BDCA- Figure 2C ). However, the cells expressed the myeloid marker CD68 ( Figure 2C ). Additional staining helped to further define the phenotype of these cells. Indeed DC-SIGN þ cells in R2 (see Figure 1A) 
DC-SIGN Is Induced on Resident Alveolar M/s upon M. tuberculosis Infection
We next sought to address whether the DC-SIGN þ M/s detected in BALs from patients with TB were resident recruited from the circulation during infection. Peripheral blood mononuclear cells (PBMCs) from patients with TB (n ¼ 3) were analysed for DC-SIGN expression by flow cytometry. DC-SIGN could be detected neither in these cells nor in PBMCs from healthy blood donors (results from one representative experiment is shown in Figure 3A) . To assess the induction hypothesis, DC-SIGN À alveolar M/s were purified by adherence from patients with asthma (n ¼ 3). Cells were then infected with M. tuberculosis at a MOI of 1 bacterium/cell, or treated with IL-4, TNF-a, or E. coli-derived LPS. IL-4 was used as a control because this cytokine has been shown to induce DC-SIGN expression in human monocytes [22] . TNF-a was used to assess whether an inflammatory context, like the one encountered in lungs from patients with TB, could induce DC-SIGN. Finally, LPS was included in order to assess whether TLR ligation may result in DC-SIGN induction, as recently reported in human circulating blood monocytes [23] . Flow cytometry analysis after 48 h showed a marked expression of DC-SIGN on the surface of the cells, both when infected with M. tuberculosis and when treated with IL-4, as compared to untreated cells ( Figure 3B ). By contrast, neither TNF-a-nor LPS-treated cells were found to express the lectin. Interestingly, in cells infected with a GFPexpressing strain of M. tuberculosis, both GFP þ (infected) and GFP À (uninfected) cells were found DC-SIGN þ , indicating that DC-SIGN induction likely relies on a soluble factor secreted by the host and/or the pathogen and that has yet to be identified. RT-PCR analysis of the DC-SIGN transcript at various times post-infection ( Figure 3C ) further confirmed that M. tuberculosis infection induces DC-SIGN expression in resident alveolar M/s as soon as 1 h after infection. Because IL-4 and IL-13 were previously shown to induce DC-SIGN expression in monocytes [22] , we wished to assess whether these cytokines might account for DC-SIGN expression by alveolar M/s in vivo in the lungs of patients with TB. We collected BAL fluids from a number of patients with TB or with other pathologies, and we measured IL-4 and IL-13 amounts by ELISA. IL-4 was detected in some samples, but without any apparent correlation with either the pathology or the amount of DC-SIGN-expressing alveolar M/s in the corresponding samples (Table 1) . IL-13 was not detectable in all samples tested (data not shown). This indicates that IL-4 and IL-13 are likely not responsible for DC-SIGN induction in vivo in the lungs of M. tuberculosis-infected patients.
DC-SIGN Mediates M. tuberculosis Binding to Alveolar M/s from Patients with TB
We next wished to evaluate the possible functional consequences of DC-SIGN induction in alveolar M/s in patients with TB. DC-SIGN has previously been shown to be a major M. tuberculosis receptor on human MoDCs [7] . We thus evaluated lectin's contribution to mycobacterial binding to and entry into DC-SIGN Figure 4C ). Anti-DC-SIGN antibodies could fully inhibit mycobacterial binding to DC-SIGN-expressing cells, whereas they had virtually no effect on binding to THP1 cells. Altogether, these results indicate that DC-SIGN expression renders M/s, and in particular alveolar M/s in the lungs of patients with TB, more susceptible to infection than their DC-SIGN À counterparts. Confocal microscopy examination of alveolar M/s infected with GFP-expressing M. tuberculosis and subsequently immunostained for DC-SIGN, showed, as in MoDCs [7] , a marked recruitment of the lectin at the site of bacterial attachment and in the nascent phagosome ( Figure  4D , upper and middle panels), followed by exclusion of the receptor from the mycobacterial vacuole once the bacillus was engulfed, most likely as a result of receptor recycling ( Figure 4D , lower panels).
DC-SIGN Does Not Mediate IL-10 Secretion in Alveolar M/s
Besides its function in pathogen recognition and phagocytosis, DC-SIGN has been proposed to play a role in triggering intracellular signals and cytokine secretion. In particular, it has previously been reported that DC-SIGN ligation by LAM synergizes with TLR4 ligation by LPS to potentiate IL-10 secretion by MoDCs [8] . We sought to determine whether this might also be the case in alveolar M/s, which also express TLR4 (see Figure 2C ). Alveolar M/s from three patients with TB were purified by adherence and stimulated for 18 h with LPS alone or LPS and M. tuberculosisderived LAM, in the presence or absence of anti-DC-SIGN or control isotype antibodies. Although basal IL-10 production differed among M/ preparations, treatment of the cells with LPS resulted in a slight increase in IL-10 secretion in all cases, as revealed by ELISA ( Table 2) . Treatment of the cells with LAM alone had virtually no effect on IL-10 production. By contrast with what has been reported in MoDCs [8] , LAM did clearly not synergize with LPS to induce production of the cytokine by alveolar M/s (Table 2 ). This was confirmed by measuring IL-10 in BAL fluids from patients with TB or with other pathologies (Table 3) . IL-10 was detected in some samples but not systematically in samples from patients with TB that contained DC-SIGN-expressing M/s. Our results strongly suggest that DC-SIGN þ M/s arise from induction of the DC-SIGN gene during infection. IL-4 and IL-13, two cytokines known to induce DC-SIGN expression in monocytes [22] , are unlikely to account for DC-SIGN expression by alveolar M/s in patients with TB, because these cytokines were either not detected (IL-13) or detected in variable amounts and independently of pathology (IL-4) in BAL fluids from a number of different patients. Recently, DC-SIGN induction has been demonstrated in human circulating blood monocytes treated with TLR agonists [23] . This is unlikely to be the case here because we have shown that LPS treatment of DC-SIGN À alveolar M/s obtained from individuals without TB could not induce DC-SIGN expression in these cells (see Figure 3B ). Inflammation alone is unlikely to induce DC-SIGN, because alveolar M/s from patients with asthma or sarcoidosis were mostly DC-SIGN À , whereas these diseases are characterized by a marked inflammatory response in the lungs. The fact that both M. tuberculosis-infected and uninfected alveolar M/s up-regulate DC-SIGN during ex vivo infection (see Figure 3B ) is of interest, as it strongly suggests that soluble factor(s) from the host and/or the microbe can induce DC-SIGN in bystander DC-SIGN À M/s. These factors will have to be defined in future studies. In particular, the role of M. tuberculosis-derived lipids and proteins that are secreted by the bacterium prior to uptake by host cells and from inside infected cells [24, 25] will have to be investigated. In addition, the possible role of host factors, such as IL-15, will have to be examined in this respect. Indeed, IL-15 has recently been shown to induce DC-SIGN expression in human monocytes in vitro [23] , and alveolar M/s from patients with TB have been reported to produce this cytokine ex vivo [26] . So far, mycobacterial receptors on M/s have been mostly characterized using model M/s, namely mouse bone marrowderived or human monocyte-derived M/s [27] . Very few reports are available on mycobacterial receptors on alveolar M/s, and all of them used cells from healthy individuals or laboratory animals. The main mycobacterial receptors identified on human alveolar M/s are CRs, especially CR4 and CR3 on human cells [28] [29] [30] , the surfactant protein A receptor [31] , and the mannose receptor [32] . Other studies in murine alveolar M/s confirmed these findings and added other receptors, such as scavenger receptors, to the list [33] . However, to our knowledge, ours is the first study of M. tuberculosis receptors on alveolar M/s in patients with TB. Our results suggest a novel scenario of alveolar M/ infection during TB. In this scenario, CRs likely mediate most of cell infection in a naive host, and DC-SIGN-expressing M/s become privileged target cells for the bacillus once the infection is established. Furthermore, DC-SIGN induction in bystander cells may be of advantage for the tubercle bacillus to increase its intracellular territory inside the infected host.
Apart from pathogen binding, DC-SIGN may play a role in signal transduction. In particular, DC-SIGN ligation by the mycobacterial lipoglycan LAM has been reported to potentiate TLR-4-mediated IL-10 secretion by LPS-stimulated MoDCs [8] . However, treatment of LPS-stimulated alveolar M/s with LAM did not result in an increase of IL-10 production, which remained relatively low in both stimulated and untreated cells. Moreover, IL-10 was not detected in BAL fluids from patients with TB (Table 3 ). This is in accordance with previous studies reporting that IL-10 is detected in comparable amounts in BALs and lung biopsies from TB patients, and from healthy individuals [34] . IL-10 production is known to be low in M/s as compared to in DCs. The discrepancy between our results, that show no role of DC-SIGN in IL-10 secretion, and those from Geijtenbeek et al. [8] , who reported such a role, likely relies on the different cell types used in the two studies. Our results do not exclude the possibility that DC-SIGN may participate in IL-10 production by DCs in patients with TB, especially in the lymph nodes. This possibility will have to be further explored and may have important local consequences, including down-modulation of the local inflammation due to infection, either directly or by driving T lymphocytes toward a regulatory phenotype [35, 36] . In conclusion, our study reveals that during the natural course of TB in human lungs, soluble host and/or mycobacterial factor(s) induce DC-SIGN expression by alveolar M/s, which renders the cells highly prone to infection by the tubercle bacillus. DC-SIGN induction in alveolar M/s may have important consequences on lung colonization by M. tuberculosis, as well as on host immune and inflammatory responses, which will require further investigation in cell and animal models, as well as in patients with TB.
Patient Summary
Background Tuberculosis (TB) is one of the most common major infectious disease today. It is estimated that two billion people-or onethird of the world's population-are chronically infected without active symptoms. Nine million new cases of active disease are diagnosed annually, resulting in two million deaths, mostly in developing countries. TB is predominantly a lung disease. It is caused by a microbe called Mycobacterium tuberculosis, which infects lung cells. Patients with active disease easily infect others through coughing, sneezing, and spitting.
Why Was This Study Done? Most of what we know about how Mycobacterium infects lung cells during the early stages of TB comes from animal studies or studies in healthy volunteers. In this study, the researchers wanted to examine whether lung cells from patients with TB were different from those of healthy people or those with different lung diseases, and what this might tell us about the way the infection spreads in the lung. In particular, they looked at the surface of the lung cells, because this is the part directly involved in the first contact with Mycobacterium.
What Did the Researchers Do and Find? They studied 74 individuals: 40 had TB, 25 had other inflammatory lung diseases, and nine had neither active TB nor lung inflammation and served as healthy ''controls.'' The patients underwent a procedure (called bronchoalveolar lavage) that washes out some of the secretions and cells from the lower respiratory tract. The researchers then analysed the cells in different ways. They concentrated on a type of cell called a macrophage (the natural target of Mycobacterium) and found that macrophages from patients with TB had much more of a particular protein called DC-SIGN on their surface than macrophages from patients with other diseases or from the control individuals. They then took macrophages from a control individual (which thus had very low levels of DC-SIGN) and infected them with Mycobacterium under laboratory conditions. The researchers found that shortly after infection, not only the infected cells but also some of their neighbours started to display DC-SIGN on their surface. The researchers also found that having DC-SIGN on the surface made uninfected cells much more susceptible to infection.
What Does This Mean?
The results suggest that DC-SIGN has an important function in amplifying TB infection in the lung. In the long run, understanding how Mycobacterium infects patients and either makes them ill or establishes a chronic infection without acute symptoms should help with the development of new or better ways to prevent infection or treat disease.
